Biologic Therapy: Hematopoietic Growth Factors, Retinoids, and Monoclonal Antibodies


Biologic therapies are an increasingly important part of cancer treatment. In this chapter, we review the current status of studies of colony-stimulating factors (CSFs), erythropoietin (Epogen, Procrit), thrombopoietin, the retinoids, and monoclonal antibodies (MoAbs). The interferons, interleukin-2 (IL-2, aldesleukin [Proleukin]), and adoptive cellular immunotherapy are discussed in a separate chapter.

Hematopoietic Growth FactorsRetinoidsMonoclonal AntibodiesReferences

Biologic therapies are an increasingly important part of cancer treatment. In this chapter, we review the current status of studies of colony-stimulating factors (CSFs), erythropoietin (Epogen, Procrit), thrombopoietin, the retinoids, and monoclonal antibodies (MoAbs). The interferons, interleukin-2 (IL-2, aldesleukin [Proleukin]), and adoptive cellular immunotherapy are discussed in a separate chapter.

Further work in this field will include study of the normal physiologic functions of cytokines. Understanding how dysregulation of cytokine function participates in the development of pathologic states may lead to the identification of additional clinical applications. Combination therapies exploiting complementary actions and interactions among naturally occurring molecules promise an added dimension to biologic therapy. Testing of new molecules, particularly those belonging to the ever-enlarging interleukin family, will continue and may yield additional therapeutic opportunities.

Hematopoietic Growth Factors

Hematopoietic growth factors are a family of glycoproteins with important regulatory functions in the processes of proliferation, differentiation, and functional activation of hematopoietic progenitors and mature blood cells [1]. The concept of humoral control of hematopoiesis dates back to the work of Carnot and Deflandre in 1906, who demonstrated that erythropoiesis is stimulated by a humoral factor, much later called erythropoietin, present in the serum of anemic rabbits [2]. In the 1960s, Bradley and Metcalf [3] developed an in vitro bone marrow culture system and observed the formation of cell colonies from hematopoietic progenitors. This hallmark development ultimately facilitated the characterization of a variety of hematopoietic growth factors known as CSFs. The subsequent development of molecular techniques led to genetic cloning of these factors and a large supply of recombinant molecules.

As shown in Table 1, the hematopoietic growth factors include erythropoietin, the CSFs, various interleukins (IL-1 to IL-13), stem-cell factor (SCF) newly described thrombopoietin (c-Mpl ligand) [4], and flt-3/flk-2, a growth factor for early progenitor cells [5]. The CSFs include granulocyte CSF (G-CSF, filgrastim [Neupogen]), granulocyte-macrophage CSF (GM-CSF, sargramostim [Leukine]), multipotential CSF (multi-CSF, also known as IL-3), and monocyte macrophage CSF (M-CSF, also known as CSF-1). Substantial clinical data have accrued on the four CSFs and erythropoietin, and these molecules have already had a major impact on therapy for hematologic and oncologic disease.

Target cell or activityª
Induces other growth factors
T-cell growth factor
Interleukin-3 (multi-CSF)
Multipotent progenitors
B-cell growth factor
Eosinophil differentiation factor
B-/T-cell growth and differentiation; megakaryocytes
B-/T-cell precursor growth
Neutrophil chemotactic factor
T-cell growth factor; megakaryocytes and burst-forming units-erythrocytes
Cytokine synthesis inhibition in natural-liller (NK) and T-cells
B-cells, multipotent progenitors, and megakaryocyte growth
Stimulates natural-killer and cytotoxic T-cells
Granulocyte colony-stimulating factor (G-CSF)
Neutrophil growth and activation
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Growth and activation of neutrophils and macrophages
Erythroid growth and differentiation
SCF (c-
Stem-cell factor


The hematopoietic growth factors have pleiotropic effects on the proliferation, differentiation, and functional activation of blood cells. They interact at various levels of the hematopoietic differentiation cascade, from multipotent progenitors to mature cells [6].

Each growth factor is encoded by a specific gene. The biologic effects of the growth factors are mediated through specific receptors on the surfaces of target cells. The receptor molecules are also encoded by specific genes, some of which have been cloned. The major cellular sources of the growth factors are monocytes, macrophages, T lymphocytes, endothelial cells, and fibroblasts. They are present and produce growth factors at multiple sites in the body. Erythropoietin production appears to be more restricted, however, with the predominant sources in the adult being the peritubular cells of the kidneys and the Kupffer cells of the liver.

Most growth factors stimulate more than one lineage. This ability to stimulate multiple cell lineages may be related to shared elements in receptor subunits. The receptors for GM-CSF, IL-3, and IL-5 are composed of a ligand-specific alpha chain and a common beta chain. Growth factors can be classified according to the level at which they act in hematopoiesis. Late-acting lineage-specific factors act on maturing cells. Erythropoietin, IL-5, and monocyte-macrophage CSF are examples of such factors. G-CSF regulates the proliferation and maturation of neutrophil progenitors but also acts with other factors to support the proliferation of primitive, dormant progenitors. GM-CSF, IL-3, and IL-4 are examples of intermediate-acting lineage-nonspecific factors that support the proliferation of multipotential progenitors. IL-6, IL-11, IL-12, G-CSF, and SCF act synergistically with IL-3 to induce dormant primitive progenitors to enter the cell cycle [7,8].

Erythropoietin promotes the proliferation and differentiation of committed erythroid progenitors. It may also interact with other hematopoietins to stimulate megakaryocytes in vitro. In vivo, erythropoietin produces consistent and sustained increases in erythropoiesis and hematocrit.

In addition to stimulating cell proliferation and differentiation, CSFs also affect cell survival and functional activation. GM-CSF sustains viability and potentiates the functions of neutrophils, eosinophils, and macrophages [9]. G-CSF also potentiates the function of mature neutrophils but, unlike GM-CSF, appears not to increase the neutrophil half-life [10]. M-CSF enhances monocyte production of other cytokines, such as interferon, tumor necrosis factor, and CSFs themselves [11]. Indeed, virtually every function of granulocytes and macrophages that has been studied is modulated to some degree by G-CSF, GM-CSF, or M-CSF. IL-3 may regulate the function of eosinophils and monocytes [12]. Erythropoietin does not appear to alter the function of erythrocytes.

Clinical Applications

The availability of large quantities of recombinant growth factors has facilitated the exploitation of their biologic properties in the treatment of disease. G-CSF, GM-CSF, and erythropoietin have all been approved for clinical use for specific indications. A list of these indications and some investigational uses are summarized in Table 2.

Approved indications

Indications under investigation

Approved indications

Indications under investigation

Approved indications

Indications under investigation

Abrogation of Myelosuppression After Chemotherapy: The concept of using growth factors to mitigate the myelosuppressive effects of chemotherapy has generated a great deal of excitement. The potential of CSFs to reduce the morbidity and mortality from chemotherapy and to allow dose escalation has been energetically explored.

Important studies have now established that G-CSF is able to abrogate or accelerate recovery from chemotherapy-induced neutropenia. For example, in a study of G-CSF following MVAC (methotrexate, vincristine [Oncovin], doxorubicin [Adriamycin, Rubex], and cisplatin [Platinol]) chemotherapy for urothelial tumors, the administration of therapy on schedule was possible in all patients receiving G-CSF but in only 29% of patients not receiving G-CSF [13]. The occurrence of mucositis was also diminished in the treated group.

In a study of patients with small-cell lung cancer, the duration of neutropenia was shorter and the number of febrile neutropenic episodes was lower in the G-CSF-treated group than in the placebo group [14]. The treated patients also spent fewer days in the hospital and received fewer antibiotics. Morstyn et al [15] confirmed the attenuation of neutropenia in patients treated with high-dose melphalan, even when the G-CSF was given as late as 8 days after chemotherapy.

GM-CSF has also produced encouraging results in the setting of chemotherapy-induced neutropenia. In comparisons with historic controls and in comparison between sequential courses of chemotherapy with and without GM-CSF, shorter durations of neutropenia and higher nadir neutrophil counts have been consistently observed in the treatment cycles with GM-CSF [16,17]. Despite the biologic data indicating that GM-CSF acts on early progenitors, no consistent enhancement of platelet recovery has been noted.

Autologous Bone Marrow Transplantation: Growth factors have been investigated for their ability to lessen myelosuppression associated with high-dose chemotherapy and autologous bone marrow rescue. G-CSF and GM-CSF have produced similar results in this setting. Studies have shown that time to neutrophil recovery in patients with Hodgkin's disease and lymphoid malignancies was reduced by these growth factors when compared with historic controls [18,19]. The number of febrile days and days in the hospital as well as the incidence of infection were also reduced. Toxic effects to organs were decreased, presumably as a result of shorter neutropenic periods. The ability of GM-CSF to enhance hematologic reconstitution has been confirmed in prospective, randomized trials [20,21].

G-CSF treatment after allogeneic bone marrow transplantation (BMT) has been shown to reduce the duration of neutropenia. Patients who received G-CSF had fewer infections and required less antibiotic treatment and shorter hospitalization than patients who did not receive G-CSF [22,23]. Clinical trials of G-CSF use after BMT have also indicated quicker granulocyte recovery [24-26].

Myelodysplastic Syndromes: The myelodysplastic syndromes (MDSs) are acquired primary or treatment-related neoplastic clonal stem-cell disorders characterized by ineffective hematopoiesis, dysplasia, and an increased propensity for leukemic transformation [27]. The French-American-British (FAB) classification identifies five MDS subtypes: refractory anemia, refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Chromosomal abnormalities are commonly associated with these disorders. Among the most frequent abnormality is the loss of the long arm of chromosome 5 (5q-), on which is located a cluster of growth factor-related genes, including those coding for GM-CSF, M-CSF, M-CSF receptor, IL-3, IL-4, IL-5, and platelet-derived growth factor receptor. The significance of this association is under investigation. Because most patients with MDS die of infections and bleeding complications, therapy directed at increasing the number of circulating granulocytes and platelets and increasing red-cell mass appears very attractive.

Several studies have demonstrated a predictable increase in granulocyte count with GM-CSF and G-CSF in patients with MDS [28-35]. It is obvious from these studies that G-CSF or GM-CSF therapy can reduce the number of infections in patients with MDS who are neutropenic. Randomized trials comparing GM-CSF with placebo and G-CSF with observation have been reported. Most of these patients had fewer than 15% to 20% blasts in their bone marrow. There was no improvement in survival with either G-CSF or GM-CSF, and in the G-CSF study, overall survival of G-CSF-treated patients was shorter. The effect of GM-CSF on the cytopenias has been transient, disappearing in most cases with treatment cessation.

Studies of IL-3 in patients with MDS have been conducted in both Europe and the United States [36-38]; neutrophil responses occurred in 7 of 9 European patients and in 6 of 13 US patients. Reticulocyte and platelet responses were documented in a few patients. However, these responses rarely translated into a reduction in transfusion requirements. The modest improvements in the neutrophil count detected in these studies with IL-3 were not as substantial as those induced by G-CSF and GM-CSF. It is therefore likely that IL-3 will be most effective in combination with other growth factors, and such clinical trials are ongoing.

Acute Myeloid Leukemia: Estey et al [39] found no difference in the rate of infection or complete remission in patients with acute myeloid leukemia (AML) treated with fludarabine (Fludara), cytarabine, and G-CSF compared to historic controls treated with fludarabine and cytarabine alone. GM-CSF has been administered before chemotherapy in an attempt to induce leukemic blasts to enter the cell cycle, thus rendering them more susceptible to the drugs' cytotoxic effects. Despite evidence that blast production and ara-CTP (the active triphosphate derivative of cytarabine) incorporation into DNA are increased, the survival rate of patients receiving this therapy was inferior to that of historic controls [40]. Ongoing prospective, randomized trials are investigating the effect of GM-CSF before and during induction and consolidation and during the first two cycles of maintainence chemotherapy for newly diagnosed AML [41]. In an interesting study, Giralt et al [42] were able to obtain durable remissions in patients with AML who had relapsed after allogeneic BMT with G-CSF treatments.

Other Hematologic Disorders: Aplastic anemia is characterized by peripheral blood cytopenias and bone marrow hypoplasia, thus representing another potential target for CSF therapy. Vadhan-Raj et al [43] showed that leukocyte counts improved in all patients treated with GM-CSF. No significant effects were observed in other cell lineages. The increases in leukocyte counts, which were accompanied by enhanced granulocyte function, persisted only for the duration of the GM-CSF infusion. Other investigators demonstrated that GM-CSF therapy could not induce hematopoiesis in patients with the most severe form of aplastic anemia [44]. Very low doses of GM-CSF (5 to 20 µg/m²/d) have also successfully increased neutrophil counts in nearly 50% of patients with aplastic anemia [45]. Further investigation of GM-CSF in combination with other growth factors is warranted.

IL-3 has also been studied as a therapy for aplastic anemia. Ganser and co-workers [46] found increases in leukocyte counts in all nine patients treated. Platelet responses varied and included a transient decline in two patients. Kurzrock et al [36,47] have reported neutrophil responses in approximately one third of patients and platelet or reticulocyte responses in 10% of patients with aplastic anemia receiving IL-3. These effects were often modest and delayed in onset, although they persisted longer after cessation of IL-3 than did the effects of GM-CSF therapy. IL-3 combined with GM-CSF appears promising for increasing platelet counts as well as granulocyte counts in patients with aplastic anemia [48].

G-CSF has revolutionized therapy for the chronic neutropenias. A number of reports on cyclic neutropenia, congenital neutropenia, and idiopathic neutropenia have confirmed neutrophil responses in virtually 100% of patients treated with G-CSF, and resolution of infectious complications has been observed [47]. GM-CSF produces less satisfactory results, with eosinophilia predominating over neutrophil responses; one report suggested, however, that very low doses (0.3 µg/kg/d) may be more effective than standard doses [49].

Anemia: Erythropoietin was first used clinically in patients with anemia and chronic renal failure who were undergoing dialysis. It has shown consistent, sustained success in improving the hematocrit in this setting, presumably because the production of erythropoietin is impaired along with the impairment of other renal functions [50]. In contrast to the clinical settings in which CSFs are used, renal failure represents a true erythropoietin deficiency state.

Anemia frequently accompanies malignant disease, although endogenous erythropoietin production is not usually impaired in this setting. Miller et al [51] have shown, however, that the magnitude of the erythropoietin response in patients with cancer and anemia is blunted, compared with that of patients with iron-deficiency anemia. Patients with hematologic malignancies and anemia can have a wide range of endogenous erythropoietin levels, and a variety of contributory mechanisms of anemia probably exist [47-52]. Nonetheless, treatment of this group with erythropoietin has produced some encouraging data. In one study, 11 of 13 anemic patients with multiple myeloma responded to erythropoietin, with improvements in hemoglobin levels [53]. Less promising results were obtained in patients with MDS. Indeed, in our studies, only 2 of 16 patients with MDS responded [52]. Erythropoietin has been successful, however, in abrogating the anemia associated with therapy for acquired immunodeficiency syndrome (AIDS) therapy [54].


The toxic effects of growth factors have been reviewed recently [20]. Unfortunately, no direct comparisons of G-CSF and GM-CSF have been performed. However, comparing their toxicities in different studies using equally effective doses in the same clinical settings reveals greater toxicity after GM-CSF administration [20]. The first dose of GM-CSF may be accompanied by flushing, tachycardia, hypotension, dyspnea, hypoxemia, musculoskeletal pain, and nausea in a small subset of patients. This first-dose effect is more common with intravenous administration. More important, GM-CSF can induce fever and chills, which are difficult to distinguish from the signs and symptoms of infection. Other complaints include lethargy, myalgia, bone pain, and anorexia, but they are usually mild. A capillary leak syndrome characterized by edema, effusions, and inflammation may develop. Other rare side effects of GM-CSF include exacerbation of thrombocytopenia and reactivation of autoimmune disorders. Doses lower than 5 µg/kg are usually reasonably well tolerated, whereas higher doses more frequently produce severe side effects.

The most frequent G-CSF toxicity is bone pain, which is more common with intravenous administration. Fever, rash, and arthralgia are uncommon. Mild splenomegaly may occur, particularly with long-term use of G-CSF. Thrombocytopenia also has been reported, albeit rarely. Doses between 1 and 20 µg/kg are usually well tolerated. At doses higher than 30 µg/kg, excessive leukocytosis typically occurs.

Interleukin-3 (IL-3) is well tolerated at doses lower than 1,000 µg/m²/d, although low-grade fever and chills occur in a high percentage of patients. Headaches are more frequent at higher doses. Uncommon side effects include bone pain, edema, and nausea, all of which are generally mild.

Erythropoietin has caused very few side effects, even with long-term usage. Iron deficiency does occur, however, in patients with insufficient iron stores.


Retinoids are substances structurally or functionally related to vitamin A, or retinol. They exert profound effects on the growth, maturation, and differentiation of many cell types, both in vivo and in vitro [55]. Vitamin A is a vital factor in normal embryogenesis, and it influences limb development and growth pattern. The effects of retinoids are mediated by two classes of nuclear retinoic acid receptors, termed RAR and RXR. Each of these subclasses has subtypes designated alpha, beta, and gamma. These receptors are ligand-inducible, transcription-enhancer factors belonging to the nuclear receptor superfamily, which includes thyroid and steroid hormone receptors. Cytoplasmic retinoic acid-binding proteins are important in the mediation of some of the effects of retinoids. However, not all tissues responsive to retinoic acid possess this protein (eg, HL-60 cells).

Retinoids reportedly induce differentiation and/or suppression of proliferation of many cell lines, including embryonal carcinoma, leukemia, melanoma, neuroblastoma, and breast carcinoma. The best studied line is HL-60, which can be induced to differentiate to granulocytes expressing such functional characteristics as phagocytosis, complement receptors, chemotaxis, and the ability to reduce nitroblue tetrazolium. Synergy has been seen when retinoids were combined with vitamin D and its analogs as well as in combination with other cytokines [56,57].

Clinical Applications

Chemoprevention: Sporn et al [58] were the first to use the term chemoprevention, which can be defined as the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer. This subject was recently reviewed by Lippman et al [59].

A significant amount of data has accumulated over the past several years regarding the role of retinoids as chemopreventive agents, mainly in the setting of head and neck and lung cancers. Patients with a history of cancer of the head and neck and lungs are at a significantly increased risk of developing a second primary tumor. This is thought to be due to the “field cancerization” effect, in which diffuse injury to the epithelia results from the carcinogen exposure.

The ineffectiveness of current therapy for lung cancer also prompted studies evaluating the role of retinoids in preventing lung cancer development [60]. In a randomized, placebo-controlled trial, Hong and colleagues [61] have shown a significant decline in the incidence of second primary tumors with the use of isotretinoin 50 to 100 mg/m²/d for 1 year in patients with treated head and neck cancers. Pastorino et al [62] evaluated retinyl palmitate (300,000 IU/d for 1 year) in patients with resected stage I lung cancer. There was a significant decline in the number of second primary tumors in patients who received retinyl palmitate, compared with a control group who received placebo. Bolla et al [63], however, could not demonstrate any beneficial effects of etretinate, a synthetic retinoid, on the incidence of second primary tumors in patients with a history of squamous-cell carcinoma of the oral cavity or oropharynx. The role of retinoids as chemopreventive agents will be better defined upon completion of the large multicenter trials now under way (the North American Intergroup Lung Study and the European EUROSCAN study)[64].

In addition to their use in chemoprevention, retinoids have been used to treat various malignant diseases. Table 3 summarizes some of the data from these studies.

Response rate (%)
Acute promyelocytic leukemia
Early relapse (70,82-86]
Juvenile chronic myelogenous leukemia
Small number of patients (10)[75]
Non-Hodgkin's lymphoma
Significant responses in T-cell lymphomas only [73,87,88]
Squamous-cell carcinoma of the cervix
Treatment combined with alpha interferon [72]
Squamous-cell carcinoma of skin
Improved response in combination with alpha interferon [71,89]

Acute Promyelocytic Leukemia: Classified as M3 in the FAB classification system, acute promyelocytic leukemia (APL) is a relatively uncommon leukemia. It is characterized by a propensity for coagulopathy and a high death rate from bleeding diatheses during induction. Morphologically, APL cells have abundant dense granules and Auer rods. Cytogenetic analysis reveals t(15;17) in the vast majority of patients. In instances in which no cytogenetic abnormality is present, more sensitive techniques, such as Southern blotting and reverse transcriptase-polymerase chain reaction amplification, reveal a characteristic RAR-alpha/PML gene rearrangement. The retinoic acid receptor RAR-alpha gene is located on the long arm of chromosome 17. The PML gene is located on chromosome 15. The t(15;17) translocation produces a recombinant gene, PML-RAR-alpha. The PML-RAR-alpha gene product is widely thought to be responsible for the differentiation block seen in APL blasts. The underlying mechanism or mechanisms of action of the block are still unknown [65].

APL has traditionally been treated with anthracyclines with or without cytarabine. This treatment has a high complete remission rate, with a reported long-term survival of 30% to 40% [66]. Most treatment failures are due to early deaths from bleeding and infectious complications secondary to the aplastic state produced by induction chemotherapy.

All-trans retinoic acid (ATRA) has been successfully used to achieve complete remission in most patients with APL morphology and PML-RAR-alpha gene rearrangement [67]. ATRA therapy results in the terminal differentiation of APL blasts into functionally mature granulocytes. Furthermore, within the first 48 hours of treatment, ATRA therapy corrects the coagulopathy associated with APL. ATRA induces complete remission in 3 to 4 weeks of therapy in more than 90% of patients with APL [68]. De novo resistance to ATRA is very rare. ATRA therapy, unlike chemotherapy, does not produce an aplastic phase, thereby reducing the occurrence of infectious complications. ATRA therapy alone, however, has a high early (1 to 12 months) relapse rate, approaching virtually 100%. Recent studies have suggested that a combination of ATRA and chemotherapy may be better than either alone in terms of survival [69,70]. Patients whose disease relapses after ATRA therapy are generally resistant to retreatment with ATRA.

The mechanisms underlying ATRA sensitivity of APL blasts and the subsequent development of resistance are still not well defined. The PML-RAR-alpha gene product has been implicated in both leukemogenesis and response to ATRA. The development of resistance to ATRA is at least partly explained by the decline in drug levels due to the increased metabolism of ATRA during prolonged therapy [65].

Other Malignancies: Using a combination of alpha interferon (IFN-alfa) and isotretinoin in patients with advanced squamous-cell carcinoma of the skin and cervix, Lippman et al [71,72] obtained significant responses. Cheng et al [73] investigated the use of 13-cis retinoic acid in patients with non-Hodgkin's lymphoma. In this study, T-cell lymphomas responsed, but B-cell lymphomas did not. Kurzrock et al [74] demonstrated no benefit of ATRA treatment for patients with MDS. Castleberry et al [75] used ATRA to treat juvenile chronic myelogenous leukemia and obtained lasting remissions in 5 of 10 patients (two complete remissions and three partial remissions).


Retinoids are highly teratogenic compounds and therefore must be used with the utmost caution in women of child-bearing age. Apart from this serious side effect, retinoic acid toxicities are generally mild. Drying of the skin and mucous membranes occurs in virtually all patients. Arthralgias, hypertriglyceridemia, elevated liver function values, skin rashes, and mild hair loss occur in 10% to 25% of patients. More rarely, corneal opacities, exfoliation, pseudotumor cerebri, and proteinuria have occurred.

Retinoic Acid Syndrome

Retinoic acid syndrome (RAS), which is manifested as fever, respiratory distress, hyperleukocytosis, edema, pleural and pericardial effusions, hypotension, and renal failure, may occur in up to 20% of patients with APL treated with ATRA [76]. It occurs mainly within the first 3 weeks of treatment. Patients exhibiting hyperleukocytosis at the start of treatment have an increased risk of developing RAS. ATRA administered concomitantly with chemotherapy is beneficial in these patients [77]. High doses of corticosteroids given at the first sign of RAS were also beneficial.

Monoclonal Antibodies

Hybridoma technology has provided a reliable system for the production of large quantities of antibodies of defined specificity (MoAbs). Hybridoma formation requires the fusion of B lymphocytes from immunized mice and myeloma cells, resulting in immortalized MoAb-producing cells [78]. Human B lymphocytes have also been used to create chimeric hybridomas; however, this technique remains difficult. Genetically engineered chimeric “humanized” MoAbs (MoAbs with a murine complementarity-determining region attached to a human immunoglobulin molecule) have been developed in an attempt to reduce the immunogenicity of murine MoAbs.

Antibodies are capable of binding with high affinity to specific determinants. The consequences of antibody binding vary and include (1) direct neutralization of the target (as in the case of certain viruses or toxins), (2) indirect mediation of immune damage by means of complement activation, and (3) activation of cellular cytotoxicity by other immunocompetent cells (antibody-dependent cell cytotoxicity). Variables influencing the outcome include the antibody isotype, binding affinity, and target epitope frequency.

The first step in monoclonal antibody therapy is to choose an appropriate target for antibody specificity. The optimum target is a tumor-specific surface antigen not expressed on normal tissue. For example, some B-cell malignancies demonstrate unique antigenic determinants by virtue of the clonal expression of immunoglobulin molecules on the malignant cells. Unique tumor determinants such as these are not found in most tumors, however, so other tumor-associated antigens have been targeted. They include differentiation antigens that are normally expressed only at specific stages of differentiation and on limited cell lineages (eg, common acute lymphoblastic leukemia antigen CD10 [CALLA], anti-T-activated cell antibody [anti-TAC]). Oncofetal antigens, including carcinoembryonic antigen (CEA) and alpha-fetoprotein, are alternative targets.

Many MoAbs do not adequately effect immune destruction of target cells alone. Thus, MoAbs have been conjugated with other agents that are cytotoxic, including toxins, chemotherapeutic agents, and radioisotopes. The resultant immunotoxins or immunoconjugates may have the potential to improve targeted cell therapy significantly. Potent protein toxins, such as ricin and diphtheria, have also been used, because they are active only after internalization into the cell. Common radioisotopes include iodine 131, yttrium 90, indium 111, and rhenium 186.

Another strategy for MoAb treatment involves targeting growth-factor receptors. Such antireceptor MoAbs compete with natural ligands functioning as autocrine growth factors, thus impairing tumor growth. Examples include anti-IL-2 receptor and antiepidermal growth factor receptor MoAbs. This strategy may also be used to deliver conjugated molecules via the cell receptor system.

Finally, MoAbs are being developed for use as diagnostic tools to locate residual tumor after treatment and to uncover occult tumors not localized by conventional methods.

Clinical Trials

The status of MoAb therapy for cancer was reviewed recently [79-91]. Table 4 summarizes some of the studies performed with MoAbs in various malignancies [90-114]. As is obvious at a glance, most of these studies were pilot or phase-I studies with small numbers of patients. The results generally have been disappointing. However, these studies have demonstrated that MoAbs can be safely administered to humans with acceptable toxicity.

Number of responders/ number treated
Scheinberg et al [90]
M195 (Cd33)
Waldmann et al [91]
Anti-TAC (CD25)
Dyer et al [92]
Carone et al [92]
Humanized M195
AML and blastic
Schwartz et al [94]
Iodine-131 M195
Vitetta et al [95]
B-43-Pokeweed anti-CD-19 viral protein
Foon et al [96]
T101 (CDS)
Klien et al [97]
Multiple myeloma
Hu et al [98]
B-cell lymphoma
Brown et al [99]
B-cell lymphoma
Miller et al [100]
Leu-1 (CD5)
T-cell lymphoma
Dillman et al [101]
T101 (CD5)
T-cell lymphoma
Kaminski et al [102]
Iodine-131-labeled anti-B1 (CD20)
B-cell lymphoma
Press et al [103]
Iodine-131-labeled B1, IF5, MB-1 + auto BMT
B-cell lymphoma
Ryan et al [104]
Halpern et al [105]
Goodman et al [106]
Jacobs et al [107]
Rhenium-186 relabeled NR-LU10 (intraperitoneal)
Dillman et al [108]
Sears et al [109]
Mellstedt et al [110]
Takahashi et al [111]
Halpern et al [112]
Dillman et al [108]
Houghton et al [113]
R24 (GD3)
Lynch et al [114]
Lung, small-cell

The initial failure of MoAb therapy may be attributable, at least in part, to the early development of human antimurine antibodies in recipients. These antibodies develop in 90% of patients after more than two treatments, greatly reducing the ability of the MoAbs to reach their target. Avascular tumor beds also prevent MoAbs from reaching the malignant tissue. Heterogeneity of tumor antigens and the mutation of antigens over time also abrogate the effectiveness of this target-specific therapy. Strategies to overcome these problems are being investigated and include the development of chimeric mouse/human MoAbs to reduce their immunogenicity.

Immunotoxins and immunoconjugates have met with modest success in vivo. Radionuclide conjugates have been used in the treatment of ovarian cancer, leukemia (anti-CD33 MoAb), non-Hodgkin's lymphoma, and brain tumors. Microscopic disease has proven more amenable to this therapy than has gross tumor. Immunotoxin therapy has most commonly used ricin. Encouraging results were observed when an anti-CD5 conjugate was administered to patients with chronic lymphocytic leukemia. Trials of ricin-linked MoAb therapy in patients with breast or colon cancer have been frustrated by the development of human antimurine antibodies and the consequent loss of MoAb efficacy. MoAbs have also been used after autologous BMT to purge tumor cells ex vivo in autologous bone marrow therapy or to select for progenitor cells in allogeneic BMT. In addition, MoAbs have been used to deplete the marrow of CD8+ cells to reduce the incidence of graft-vs-host disease.

MoAbs remain a conceptually logical approach to therapy. Further understanding of tumor immunology and advances in technology will facilitate the ongoing development of these strategies. Presently, clinical trials using chimeric “humanized” MoAbs, immunotoxins, and MoAbs conjugated to radioisotopes for diagnosis and therapy of malignant diseases are underway.



1. Metcalf D: The granulocyte-macrophage colony-stimulating factors. Science 229:16–22, 1985.

2. Carnot P, Deflandre C: Sur l'activité hémpoiétique des différents organes au cours de la régénération du sang. CR Hebd Acad Sci 143:432–435, 1906.

3. Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287–299, 1966.

4. Lok SI, Kanshansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565–568, 1994.

5. Lyman SD, James L, Johnson L, et al: Cloning of the human homologue of the murine flt-3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 83:2795–2801, 1994.

6. Groopman JE, Molina JM, Scadden DT: Hemopoietic growth factors. N Engl J Med 321:1449–1459, 1989.

7. Metcalf D: Hematopoietic regulators: Redundancy or subtlety? Blood 82:3515–3523, 1993.

8. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844, 1993.

9. Metcalf D, Begley CG, Johnson GR, et al: Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 67:37–45, 1986.

10. Lord BI, Bronchud MH, Owens S, et al: The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86:9499–9503, 1989.

11. Warren MK, Ralph P: Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony-stimulating activity. J Immunol 137:2281–2285, 1986.

12. Rothenburg ME, Owen WF Jr, Silberstein DS, et al: Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3. J Clin Invest 81:1986–1992, 1988.

13. Gabrilove J, Jacubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414–1422, 1988.

14. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170, 1991.

15. Morstyn G, Campbell L, Souza LM, et al: Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1:667–672, 1988.

16. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 310:593–598, 1989.

17. Morstyn G, Lieschke GJ, Cebon J, et al: Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Semin Hematol 26:9–13, 1989.

18. Taylor KM, Jagannath S, Spitzer G, et al: Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high dose chemotherapy under autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7:1791–1799, 1989.

19. Nemunaitis J, Singer JW, Buckner CD, et al: Use of recombinant human granulocyte-macrophage colony-stimulating factor in bone marrow transplantation for lymphoid malignancies. Blood 72:834–836, 1988.

20. Grosh WW, Quesenberry PJ: Recombinant human hematopoietic growth factors in the treatment of cytopenias. Clin Immunol Immunopathol 62:S25–38, 1992.

21. Advani R, Chao NJ, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 116:183–189, 1992.

22. Gisselbrecht C, Prentice HG, Barigalupo A, et al: Placebo controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 343:696, 1994.

23. Schueing FG, Lilleby K, Clift RA, et al: Phase I study of rhG-CSF after marrow transplantation from HLA-identical siblings. Blood 82(S1):349a, 1993.

24. De Witte T, Gratwohl A, Van Der Lely N, et al: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell depleted bone marrow transplantation. Blood 79:1359–1365, 1992.

25. Anasetti C, Anderson G, Appelbaum FR, et al: Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 82:454a, 1993.

26. Nemunaitis J, Rosenfeld C, Ash R, et al: Phase III double-blind trial of rhGM-CSF (Sargramostin) following allogeneic bone marrow transplant (BMT). Blood 82(S1):286a, 1993.

27. Kouides PA, Bennet JM: Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:485–499, 1992.

28. Vadhan-Raj S, Keating M, Le Maistre A, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552, 1983.

29. Vadhan-Raj S, Hittleman WN, Ventura C, et al: GM-CSF and myelodysplastic syndromes. N Engl J Med 319:51–53, 1988.

30. Ganser A, Seipelt G, Eder M, et al: Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 19(S4):95–101, 1992.

31. Greensberg P, Taylor K, Larson R, et al: Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS)(abstract). Blood 82(suppl 1):196a, 1993.

32. Schuster MW, Thompson JA, Larson R, et al: Randomized trial of subcutaneous GM-CSF versus observation in patients with myelodysplastic syndrome. J Cancer Res Clin Oncol 116(1):1079, 1990.

33. Willemze R, Van Der Lely H, Zwiersina H, et al: On behalf of EORTC leukemia cooperative group: A randomized phase I/II multicenter study of recombinant GM-CSF therapy for patients with myelodysplastic syndromes and relatively low risk of acute leukemia. Ann Hematol 64:173–180, 1992.

34. Estey EH, Kurzrock R, Talpaz M, et al: Effects of low dose recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on patients with myelodysplastic syndromes. Br J Haematol 77:291–295, 1991.

35. Greenberg P: Treatment of myelodysplastic syndromes with hemopoietic growth factors. Semin Oncol 19:106–114, 1992.

36. Kurzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250, 1991.

37. Ganser A, Seipelt G, Lindemann A, et al: Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462, 1990.

38. Nimer SD, Paquette RL, Ireland P, et al: A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp hematol 22(9):875–880, 1994.

39. Estey EH, Thall P, Andreef M, et al: Use of G-CSF before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without G-CSF. J Clin Oncol 12(4):671–678, 1994.

40. Estey EH, Thall P, Kantarjian H, et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C and daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246–2255, 1992.

41. Hiddemann W, Wormann B, Renter C, et al: New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors. Semin Oncol 21(suppl 16):33–38, 1994.

42. Giralt S, Escudier S, Kantarjian H, et al: Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329(11):757–761, 1993.

43. Vadhan-Raj S, Buescher S, Broxmeyer HE, et al: Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med 319:1628–1634, 1988.

44. Nissen C, Tichelli A, Gratwohl A, et al: Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood 72:2045–2047, 1988.

45. Kurzrock R, Talpaz M, Gutterman J: Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med 93:41–48, 1992.

46. Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666–676, 1990.

47. Kurzrock R, Talpaz M, Estey EH, et al: Hematopoietic growth factors in bone marrow failure states. Cancer Bulletin 43:215, 1991.

48. Talpaz M, Patterson M, Kurzrock R: Sequential administration of IL-3 and GM-CSF in bone marrow failure patients: A phase I study (abstract). Blood 84(S1):28a, 1994.

49. Kurzrock R, Talpaz M, Gutterman J: Treatment of cyclic neutropenia with very low doses of GM-CSF. Am J Med 91:317, 1991.

50. Mohini R: Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol 9:16–21, 1989.

51. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689–1692, 1990.

52. Kurzrock R, Talpaz M, Estey EH, et al: Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 5:985–990, 1991.

53. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699, 1990.

54. Fischl M, Galpin JE, Levine JD, et al: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322:1488–1493, 1990.

55. Lotan R: Retinoids and squamous cell differentiation, in Hong WK, Lotan R (eds): Retinoids in Oncology, pp 43–72. New York, Marcel Dekker Inc, 1993.

56. Tanaka Y, Shima M, Yamoka K, et al: Synergistic effect of 1,25-dihydroxyvitamin D3 and retinoic acid in inducing U937 cell differentiation. J Nutr Sci Vitaminol (Tokyo) 38:415–426, 1992.

57. Bollag W, Peck R, Frey JR: Inhibition of proliferation by retinoids: Cytokines and their combination in four human transformed epithelial cell lines. Cancer Lett 62:167–172, 1992.

58. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338, 1976.

59. Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12:851–873, 1994.

60. Benner SE, Pajak TF, Lippman SM, et al: Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: Long term follow-up. J Natl Cancer Inst 86:140–141, 1994.

61. Hong WK, Lippman SM, Itri LM: Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:825–827, 1990.

62. Pastorino V, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high dose vitamin A. J Clin Oncol 11:1216–1222, 1993.

63. Bolla M, Lefur R, Ton Van J, et al: Prevention of second primary tumors with etretinate in squamous cell carcinoma of oral cavity and oropharynx: Results of a multicentric, double-blind, randomized study. Eur J Cancer 30:767–772, 1994.

64. Benner SE, Lippman SM, Hong WK: Current status of retinoid chemoprevention of lung cancer. Oncology 9(3):205–210, 1995.

65. Grignani F, Fagioli M, Longo L, et al: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10–25, 1994.

66. Fenaux P: Management of acute promyelocytic leukemia. Eur J Haematol 50:65, 1993.

67. Degos L: Is acute promyelocytic leukemia a curable disease? Treatment strategy for long-term survival. Leukemia 8(S2):S6–8, 1994.

68. Warrel Jr RP, de The H, Wang ZY, et al: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993.

69. Fenaux P, Chastang C, Degos L, et al: All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate in prolonged remissions in newly diagnosed acute promyelocytic leukemia. Blood 80:2176–2181, 1993.

70. Kanamaru A, Takemoto Y, Tanimoto M, et al: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202–1206, 1995.

71. Lippman SM, Parkinson DR, Itri RS, et al: 13-Cis retinoic acid and interferon-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235–240, 1992.

72. Lippman SM, Kavanagh JJ, Parades-Espinoza M, et al: 13-Cis retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241–245, 1992.

73. Cheng A, Su I, Chen C, et al: Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study. J Clin Oncol 12:1185–1192, 1994.

74. Kurzrock R, Estey EH, Talpaz M: All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndromes. J Clin Oncol 11:1489–1495, 1993.

75. Castleberry RP, Emanuel PD, Zuckerman KS: A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 331:1680–1684, 1994.

76. Frankel SR, Eardey A, Warrell Jr RP, et al: The `retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 117:292–296, 1992.

77. Dombret H, Sutton L, Degos L: Combined therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytosis APL and severe visceral hemmorhage. Leukemia 6:1237–1242, 1992.

78. Koehler G, Milstein C: Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495–496, 1975.

79. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12(7):1497–1515, 1994.

80. Kuzel TM, Rosen ST: Antibodies in the treatment of human cancer. Curr Opin Oncol 6(6):622–626, 1994.

81. Caron PC, Scheinberg DA: Immunotherapy for acute leukemias. Curr Opin Oncol 6(1):14–22, 1994.

82. Warrell Jr RP, Frankel SR, Miller W, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324:1385–1393, 1991.

83. Degos L, Chomienne C, Daniel MT, et al: Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid (letter). Lancet 336(8728):1440–1441, 1990.

84. Ohno R, Yoshida H, Fukutani H: Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 7:1722–1727, 1993.

85. Castaigne S, Chomienne C, Daniel MT: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemias: I. Clinical results. Blood 76:1704–1709, 1990.

86. Huang ME, Yu-Chen Y, Shu-Rong C: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572, 1988.

87. Kessler JF, Jones SE, Levine N: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123:201–204, 1987.

88. Hoting E, Meissner K: Arotinoid-ethylester: Effectiveness in refractory cutaneous T-cell lymphoma. Cancer 62(6):1044–1048, 1988.

89. Lippman SM, Meyskens FL: Activity of 13-cis retinoic acid (Accutane) in advanced squamous cell carcinoma of the skin. Ann Intern Med 107:449–501, 1987.

90. Scheinberg DA, Lovett D, Divgi CR, et al: A phase I trial of monoclonal antibody M195 in AML: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478–490,1991.

91. Waldmann TA, Goldmann CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotropic virus 1-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for IL-2. Blood 72:1805–1816, 1988.

92. Dyer MJS, Hale G, Hayhoe FGH, et al: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431–1439, 1989.

93. Caron PC, Co MS, Bull MK, et al: Biological and immunological features of humanized M195 (Anti-CD33) monoclonal antibodies. Cancer Res 52:6761–6767, 1992.

94. Schwartz MA, Lovett OR, Render A, et al: Dose-escalation trial of M195 labeled with iodine-131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294–303, 1993.

95. Vitetta ES, Thorpe PE, Uhr JW: Immunotoxins: Magic bullets or misguided missiles? Immunol Today 14:252–259, 1993.

96. Foon KA, Schroff RW, Bunn PA, et al: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085–1093, 1984.

97. Klien B, Wijdenes J, Zhang XJ, et al: Murine anti-IL-6 monoclonal therapy for a patient with plasma cell leukemia. Blood 78:1198–1204, 1991.

98. Hu F, Epstein AL, Naeve GS, et al: A phase Ia clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B-cell malignancies. Hematol Oncol 7:155–166, 1989.

99. Brown SL, Miller RA, Horning SJ, ET al: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651–661, 1989.

100. Miller RA, Oseroff AR, Stratte PT, et al: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988–995, 1983.

101. Dillman RO, Shawler DL, Dillman JB, et al: Therapy of chronic lymphocytic leukemia and cutaneous lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881–891, 1984.

102. Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459–465, 1993.

103. Press OW, Eary JF, Appelbaum FR, et al: Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224, 1993.

104. Ryan KP, Dillman RO, DeNardo SJ, et al: Breast cancer imaging with In-111 human IgM monoclonal antibodies. Radiology 167:71–75, 1988.

105. Halpern SE, Dillman RO: Radioimmunodetection with monoclonal antibodies against prostatic acid phosphatase, in Winkler C (ed): Nuclear Medicine in Clinical Oncology, pp 164–170. Berlin, Springer-Verlag, 1986.

106. Goodman GE, Hellstrom I, Brodzinsky I, et al: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 8:1083–1092, 1990.

107. Jacobs AJ, Fer M, Su FM, et al: A phase I trial of rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 82:586–593, 1993.

108. Dillman RO, Beauregard J, Ryan KP, et al: Radioimmunodetection of cancer using indium-labeled monoclonal antibodies: International symposium on labeled and unlabeled antibodies in cancer diagnosis and therapy. Natl Cancer Inst Monogr 3:33–36, 1987.

109. Sears HF, Herlyn D, Steplewski Z, et al: Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45:5910–5913, 1985.

110. Mellstedt H, Frodin J-E, Mascci G, et al: The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 18:462–477, 1991.

111. Takahashi T, Toshiharu Y, Kitamura K, et al: Follow-up study of patients treated with antibody drug conjugate: Report of 77 cases with colorectal cancer. Jpn J Cancer Res 84:976–981, 1993.

112. Halpern SE, Dillman RO, Witztum KF, et al: Radioimmunodetection of melanoma utilizing 111-In-96.5 monoclonal antibody: A preliminary report. Radiology 155:493–499, 1985.

113. Houghton AN, Mintzer D, Cordon-Caro C, et al: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 82:1242–1246, 1985.

114. Lynch Jr TJ: Immunotoxin therapy of small-cell lung cancer. Chest 103:436–439S, 1993. 

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.